Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA

Drugs in Context

Volumn 4, Issue , 2015, Pages 1-12

  Girvan, Allicia C ^a   Carter, Gebra C ^a   Li, Li ^a   Kaltenboeck, Anna ^b   Ivanova, Jasmina ^b   Koh, Maria ^b   Stevens, Jessi ^b   Hayes Larson, Eleanor ^b   Lahn, Michael M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Bevacizumab; Cancer; First line therapy; Glioblastoma; Observational; Second line therapy; Temozolomide; Treatment patterns

Indexed keywords

ANTIDEPRESSANT AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CENTRAL STIMULANT AGENT; CHLOROQUINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; GROWTH FACTOR; IRINOTECAN; LOMUSTINE; METHOTREXATE; POLIFEPROSAN; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; FEMALE; GLIOBLASTOMA; HEALTH CARE UTILIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84938717833     PISSN: 17451981     EISSN: 17404398     Source Type: Journal    
DOI: 10.7573/dic.212274     Document Type: Article

References (39)

1. Dunn GP, Rinne ML, Wykosky J et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012;26:756-84. http://dx.doi.org/10.1101/gad.187922.112
2. Chamberlain MC, Cloughsey T, Reardon DA et al. A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012;12:421-35. http://dx.doi.org/10.1586/ern.11.188
3. Central Brain Tumor Registry of the United States (2011) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Available at: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf. [Last accessed: July 1, 2013].
4. Kutikova L, Bowman L, Chang S et al. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol. 2007;81:61-5. http://dx.doi.org/10.1007/s11060-006-9197-y
5. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96. http://dx.doi.org/10.1056/NEJMoa043330
6. National Comprehensive Cancer Network (2013) NCCN Guidelines for Treatment of Cancer by Site: Central Nervous System Cancer. Version 2.2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf [Last accessed: October 2013].
7. Filippini G, Falcone C, Boiardi A et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008;10:79-87. http://dx.doi.org/10.1215/15228517-2007-038
8. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443-9. http://dx.doi.org/10.1158/1078-0432.CCR-09-3106
9. Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer. 2013;119:3489-95. http://dx.doi.org/10.1002/cncr.28259
10. Koshy M, Villano JL, Dolecek TA et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012; 107:207-12. http://dx.doi.org/10.1007/s11060-011-0738-7
11. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507. http://dx.doi.org/10.1056/NEJMra0708126
12. Chang SM, Butowski NA, Sneed PK et al. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme. Neurosurg Focus. 2008;20:E4.
13. Gilbert MR. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches. Semin Oncol. 2011;38(suppl 4):S21-S33. http://dx.doi.org/10.1053/j.seminoncol.2011.09.008
14. Hou LC, Veeravagu A, Hsu AR et al. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20:E5. http://dx.doi.org/10.3171/foc.2006.20.4.2
15. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. http://dx.doi.org/10.1016/0021-9681(87)90171-8
16. Romano P, Roos L, Jollis J. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-9. http://dx.doi.org/10.1016/0895-4356(93)90103-8
17. Stupp R, Hegi ME, van den Bent MJ, Mason WP et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist. 2006;11:165-80. http://dx.doi.org/10.1634/theoncologist.11-2-165
18. Martin V, Liu D, Gomez-Manzano C. Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des. 2009;15:353-64. http://dx.doi.org/10.2174/138161209787315819
19. Neyns B, D'haeseleer M, Rogiers A et al. The role of cytotoxic drugs in the treatment of central nervous system gliomas. Acta Neurol Belg. 2010;110:1-14.
20. van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer. 2006;42:582-8.
21. Ray S, Bonafede MM, Mohile NA. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large us commercially insured population. Am Health Drug Benefits. 2014;7(3):140-9.
22. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010;116:3988-99. http://dx.doi.org/10.1002/cncr.25256
23. Chinot OL, de La Motte Rouge T, Moore N et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28:334-40. http://dx.doi.org/10.1007/s12325-011-0007-3
24. Nishikawa R. Standard therapy for glioblastoma - a review of where we are. Neurol Med Chir (Tokyo). 2010;50:713-9. http://dx.doi.org/10.2176/nmc.50.713
25. Specenier P. Bevacizumab in glioblastoma multiforme. Expert Rev Anticancer Ther. 2012;12:9-18. http://dx.doi.org/10.1586/era.11.179
26. Genentech, Inc (2009) Avastin® (bevacizumab) prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s0169lbl.pdf [Last accessed: October 2013].
27. Fayanju OM, Stoll CR, Fowler S, Colditz GA, Jeffe DB, Margenthaler JA. Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(10):3308-16. doi: 10.1245/s10434-013-3157-5. Epub 2013 Aug 22. http://dx.doi.org/10.1245/s10434-013-3157-5
28. Keegan KA, Zaid HB, Patel SG, Chang SS. Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States. Curr Urol Rep. 2014;15(4):394. doi: 10.1007/s11934-014-0394-5. http://dx.doi.org/10.1007/s11934-014-0394-5
29. Aizer AA, Ancukiewicz M, Nguyen PL et al. Underutilization of radiation therapy in patients with glioblastoma: predictive factors and outcomes. Cancer. 2014;120:238-43. http://dx.doi.org/10.1002/cncr.28398
30. Aneja S, Khullar D, Yu JB. The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme. J Neurooncol. 2013;112:393-401. http://dx.doi.org/10.1007/s11060-013-1068-8
31. Sherwood PR, Dahman BA, Donovan HS et al. Treatment disparities following the diagnosis of an astrocytoma. J Neurooncol. 2011;101:67-74. http://dx.doi.org/10.1007/s11060-010-0223-8
32. Irwin C, Hunn M, Purdie G et al. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol. 2007;85:339-43. http://dx.doi.org/10.1007/s11060-007-9426-z
33. Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293:557-64. http://dx.doi.org/10.1001/jama.293.5.557
34. Bock HC, Puchner MJ, Lohmann F et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33:441-9. http://dx.doi.org/10.1007/s10143-010-0280-7
35. Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg. 2011;114:587-94. http://dx.doi.org/10.3171/2010.8.JNS1081
36. Daigle K, Fortin D, Mathieu D et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed patients with glioblastoma: a report on 19 patients surviving to follow-up. Curr Med Res Opin. 2013;29:1307-13. http://dx.doi.org/10.1185/03007995.2013.823858
37. Minniti G, Scaringi C, Baldoni A et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys. 2013;86:285-91. http://dx.doi.org/10.1016/j.ijrobp.2013.02.013
38. Shah U, Morrison T. A review of the symptomatic management of malignant gliomas in adults. J Natl Compr Canc Netw. 2013;11:424-9.
39. Semrad TJ, O'Donnell R, Wun T et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106:601-8. http://dx.doi.org/10.3171/jns.2007.106.4.601